OxySure Systems Pitch Deck Teardown: A Public Company's

OxySure Systems, Inc. Corporate Presentation Analysis

The October 2015 corporate presentation for OxySure Systems, Inc. (OTCQB: OXYS) provides a comprehensive look at a medical technology company transitioning from a development stage to a commercial scaling phase. The deck is structured to validate the technology through regulatory milestones and demonstrate market demand through accelerating revenue figures.

Slide 1: Title Slide

The title slide introduces the company as OxySure Systems, Inc., using the ticker symbol OXYS. The tagline "Oxygen from Powder" immediately defines the unique selling proposition. The date, October 2015, sets the context for the financial data that follows. The visual theme of water splashes and bubbles reinforces the "clean" and "safe" nature of the chemical process used to generate oxygen.

Slide 6: Recent Milestones

This slide serves as a credibility builder. It outlines a decade of progress, starting with nine patents issued between 2006 and 2010 . Crucially, it lists regulatory successes: FDA approval (OTC), CE Marking, ANVISA (Brazil), and MOH (Israel) achieved between 2005 and 2014. The slide also notes the company went public via an S-1 in 2011/2012 and has secured distribution contracts with major industrial suppliers like Grainger, Systemax, and MSC Industrial .

Slide 11: Problems w/ Existing Emergency Oxygen

OxySure uses this slide to frame the market opportunity by highlighting the flaws of incumbents. Compressed cylinders are labeled as explosion hazards, heavy, and expensive . Chemical generators are described as highly toxic and producing high heat . The slide concludes with a price comparison: while existing solutions cost between $369 and $899 , the OxySure Model 615 is priced at $349 . This positioning suggests OxySure is both a safer and more economical choice.

Slide 16: Where Are We Today Outside US?

This slide uses a pyramid graphic to illustrate the company's global reach. The base of the pyramid includes Brazil, Turkey, and South Africa , followed by Australia, New Zealand, and the UK . The higher tiers include Netherlands, Belgium, Luxembourg, Hong Kong, Macau, and Chile . The top of the pyramid indicates "Others pending," suggesting an active pipeline of international regulatory filings and market entries.

Slide 21: Revenue Trends by Quarter

The company displays strong top-line growth here. Quarterly revenues increased from $103,327 in 3Q12 to $1,045,693 in 2Q15 . The annual revenue summary shows a jump from $269,697 in FY2012 to $2,437,402 in FY2014 . While the growth percentages are high (e.g., 568% in FY2013), the slide also shows a dip in growth to 35% in FY2014, indicating some volatility in the scaling process.

Slide 26: 2Q 2015 Financial Results

This slide provides a more sobering look at the company's profitability. Despite reaching record quarterly revenues of $1,045,693 , the company reported a net loss of $1,259,314 for the quarter. This is a significant increase in loss compared to 2Q 2014, where the loss was only $233,528 . The net loss per share improved slightly from $(.05) in 1Q 2015 to $(.04) in 2Q 2015, but the overall trend shows that expenses are outpacing revenue growth.

Slide 31: Statement of Cash Flows

The cash flow statement reveals how the company is funded. Net cash produced by financing activities was $3,923,853 , primarily driven by $2,650,001 from preferred stock and $1,461,000 from convertible notes payable . This financing allowed the company to end the period with $2,875,941 in cash , despite the operating losses. It highlights the company's dependence on capital markets to sustain operations.

Slide 36: Other Financial Items

This slide lists balance sheet strengths that might not be immediately apparent from the P&L. It notes $2 million in capital equipment off balance sheet and deferred income tax assets of $5.6 million . These items are likely intended to signal to investors that there is underlying value and future tax shields that could benefit the company once it reaches profitability.

Slide 41: Growth Strategy Next 3-5 Years

OxySure outlines a three-pronged growth strategy. First, they aim to grow "Placement Markets" by targeting the 3 million+ unit AED companion market . Second, they plan to grow "At Risk Markets" by pursuing insurance reimbursement (Medicare, private) for 100 million+ US customers. Finally, they identify new vertical mass markets including Military, Mining, Aviation, Sports, and Skin Care . The inclusion of "Strategic Alliances" at the bottom suggests they are open to partnerships to execute this broad expansion.

Slide 46: Contact Information

The final slide provides the company's headquarters address in Frisco, Texas , and contact details for their investor relations firms, Redchip Companies, Inc. and Renmark Financial Communications, Inc. . This confirms the company's focus on maintaining active communication with the public markets.

What OxySure Systems Does Well

OxySure excels at validating a complex medical technology for a general audience. By focusing on the "Oxygen from Powder" tagline, they simplify a chemical engineering feat into a digestible consumer benefit. The deck is also very transparent regarding regulatory status; listing specific agencies like ANVISA and MOH provides a level of detail that builds significant trust with institutional investors. Furthermore, the comparison slide (Slide 11) is a masterclass in positioning, clearly identifying the pain points of the status quo and offering a direct solution.

What is Missing from the Deck

Despite the 46-slide length, the 10 slides provided omit several critical pieces of information. There is no team slide in this selection, leaving investors unaware of the leadership's background in medical devices or public company management. There is also a lack of unit economics ; while we see total revenue and total loss, we don't see the gross margin per unit sold, which is vital for understanding if the company can ever reach break-even. Finally, the deck lacks a competitive landscape beyond generic categories; it does not name specific companies or brands they are competing against in the AED companion or aviation markets.

Lessons for Founders

Founders can learn two distinct lessons from this deck. First, regulatory milestones are the lifeblood of med-tech . OxySure correctly puts these front and center to prove that their technology isn't just a concept, but a legally saleable product. Second, transparency in financials is mandatory for public or late-stage companies . Even though the company is losing money, presenting the full statement of cash flows (Slide 31) shows professional maturity. However, founders should be wary of the "everything for everyone" growth strategy seen on Slide 41. Targeting military, mining, skin care, and aviation simultaneously can signal a lack of focus to some investors, who might prefer a deep dive into one high-value vertical before expanding.